Abstract
The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.
Keywords: AVI-6002, AVI-7537, AVI-7539, BCX4430, brincidofovir, Ebola, favipiravir, TKM-100802.
Graphical Abstract
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Related Books
test ebook
COVID-19: Causes, Transmission, Diagnosis, and Treatment
Computer-Aided Drug Discovery Methods: A Brief Introduction
Infectious Diseases
Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product
Marine Biopharmaceuticals: Scope and Prospects
COVID 19 – Monitoring with IoT Devices
Frontiers in Clinical Drug Research-Anti Infectives
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
41